secwatch.observer — SEC 8-K summary
======================================

Issuer:     DELCATH SYSTEMS, INC. (DCTH)
CIK:        0000872912
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001628280-25-038098
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Delcath Q2 revenue jumps 210% to $24.2M; net income $2.7M vs loss; FY25 guidance raised
--------------------------------------------------------------------------------

- Total revenue $24.2M (+210% YoY); HEPZATO KIT revenue $22.5M, CHEMOSAT $1.7M.
- Net income $2.7M vs net loss $13.7M; Non-GAAP adj. EBITDA $9.8M vs loss $0.8M.
- FY2025 revenue guidance raised to $93-96M; gross margins 83-85%; positive EBITDA and cashflow each quarter.
- Cash and investments $81.0M, no debt; activated 3 new U.S. centers (20 total, 10 accepting referrals).
- Received EU/UK authorization for clinical study of HEPZATO in metastatic colorectal cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872912/000162828025038098/0001628280-25-038098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872912/000162828025038098/dcth-20250806.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-038098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer